Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
D004087:Dihydroergotamine / Q000627:therapeutic use*; D004878:Ergotamine / Q000627:therapeutic use*; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*
D004087:Dihydroergotamine; D004878:Ergotamine